Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

191 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of Baseline Antiarrhythmic Drug on Outcomes With Ablation in Ischemic Ventricular Tachycardia: A VANISH Substudy (Ventricular Tachycardia Ablation Versus Escalated Antiarrhythmic Drug Therapy in Ischemic Heart Disease).
Parkash R, Nault I, Rivard L, Gula L, Essebag V, Nery P, Tung S, Raymond JM, Sterns L, Doucette S, Wells G, Tang ASL, Stevenson WG, Sapp JL. Parkash R, et al. Among authors: nery p. Circ Arrhythm Electrophysiol. 2018 Jan;11(1):e005663. doi: 10.1161/CIRCEP.117.005663. Circ Arrhythm Electrophysiol. 2018. PMID: 29305400 Clinical Trial.
Cardiac-resynchronization therapy for mild-to-moderate heart failure.
Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol G, Birnie DH, Sapp JL, Yee R, Healey JS, Rouleau JL; Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Tang AS, et al. N Engl J Med. 2010 Dec 16;363(25):2385-95. doi: 10.1056/NEJMoa1009540. Epub 2010 Nov 14. N Engl J Med. 2010. PMID: 21073365 Free article. Clinical Trial.
Failure rate of the Riata lead under advisory: a report from the CHRS Device Committee.
Parkash R, Exner D, Champagne J, Mangat I, Thibault B, Healey JS, Tung S, Crystal E, Simpson C, Nery PB, Sterns L, Connors S, Cameron D, Verma A, Beardsall M, Wolfe K, Essebag V, Ayala-Paredes F, Sanatani S, Coutu B, Fraser J, Toal S, Philippon F, Tang AS, Yee R, Krahn A. Parkash R, et al. Heart Rhythm. 2013 May;10(5):692-5. doi: 10.1016/j.hrthm.2013.01.018. Epub 2013 Jan 17. Heart Rhythm. 2013. PMID: 23333722
Pacemaker or defibrillator surgery without interruption of anticoagulation.
Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, Simpson CS, Ayala-Paredes F, Coutu B, Leiria TL, Essebag V; BRUISE CONTROL Investigators. Birnie DH, et al. N Engl J Med. 2013 May 30;368(22):2084-93. doi: 10.1056/NEJMoa1302946. Epub 2013 May 9. N Engl J Med. 2013. PMID: 23659733 Free article. Clinical Trial.
Is there an association between clinical presentation and the location and extent of myocardial involvement of cardiac sarcoidosis as assessed by ¹⁸F- fluorodoexyglucose positron emission tomography?
Mc Ardle BA, Birnie DH, Klein R, de Kemp RA, Leung E, Renaud J, DaSilva J, Wells GA, Beanlands RS, Nery PB. Mc Ardle BA, et al. Circ Cardiovasc Imaging. 2013 Sep;6(5):617-26. doi: 10.1161/CIRCIMAGING.112.000289. Epub 2013 Jul 24. Circ Cardiovasc Imaging. 2013. PMID: 23884290
The Canadian experience with Durata and Riata ST Optim defibrillator leads: a report from the Canadian Heart Rhythm Society Device Committee.
Bennett MT, Ha AC, Exner DV, Tung SK, Parkash R, Connors S, Coutu B, Crystal E, Champagne J, Philippon F, Yee R, Stephenson EA, Nery PB, Essebag V, Sanatani S, Redfearn D, Krahn AD, Healey JS. Bennett MT, et al. Heart Rhythm. 2013 Oct;10(10):1478-81. doi: 10.1016/j.hrthm.2013.07.050. Epub 2013 Aug 22. Heart Rhythm. 2013. PMID: 23973950
Cardiac Sarcoidosis.
Birnie D, Ha AC, Gula LJ, Chakrabarti S, Beanlands RS, Nery P. Birnie D, et al. Among authors: nery p. Clin Chest Med. 2015 Dec;36(4):657-68. doi: 10.1016/j.ccm.2015.08.008. Epub 2015 Sep 11. Clin Chest Med. 2015. PMID: 26593140 Review.
Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: The BRUISE CONTROL-2 trial.
Essebag V, Healey JS, Ayala-Paredes F, Kalfon E, Coutu B, Nery P, Verma A, Sapp J, Philippon F, Sandhu RK, Coyle D, Eikelboom J, Wells G, Birnie DH. Essebag V, et al. Among authors: nery p. Am Heart J. 2016 Mar;173:102-7. doi: 10.1016/j.ahj.2015.12.007. Epub 2015 Dec 19. Am Heart J. 2016. PMID: 26920602 Clinical Trial.
191 results